Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan
December 03, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Present at Upcoming Healthcare Conferences
November 13, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update
October 30, 2019 16:00 ET
|
Immunomedics
TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA Resubmission Targeted for Late...
Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019
October 23, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Present at the 2019 Cantor Global Healthcare Conference
October 01, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Provides Corporate Update
September 28, 2019 12:30 ET
|
Immunomedics
Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy Future Steps Include...
Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress
September 12, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress
September 04, 2019 07:45 ET
|
Immunomedics
MORRIS PLAINS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in Upcoming Healthcare Conferences
August 28, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update
August 07, 2019 16:00 ET
|
Immunomedics
ASCENT Study Reached Target Patient Enrollment First Patients Dosed in TROPICS-02 Study in HR+/HER2– Metastatic Breast Cancer Trop-2-Enriched TROPICS-03 Basket Study Initiated with Non-Small Cell...